{"prompt": "['OSTPDL1', 'Page 54 of 60', '9.5', 'Duration of Response', 'Duration of overall response: The duration of overall response is', 'measured from the time measurement criteria are met for CR or PR', '(whichever is first recorded) until the first date that recurrent or', 'progressive disease is objectively documented (taking as reference for', 'progressive disease the smallest measurements recorded since the', 'treatment started).', 'The duration of overall CR is measured from the time measurement', 'criteria are first met for CR until the first date that progressive disease is', 'objectively documented.', 'Duration of stable disease: Stable disease is measured from the start of', 'the treatment until the criteria for progression are met, taking as', 'reference the smallest measurements recorded since the treatment', 'started, including the baseline measurements.', '9.6', 'Toxicity Evaluation Criteria', 'This study will utilize the CTCAE v4.03 for toxicity and performance', 'reporting. A copy of the CTCAE v4.03 can be downloaded from the CTEP', 'home page (http://ctep.info.nih.gov). Additionally, the toxicities are to be', 'reported on the appropriate data collection forms.', '10.0 OFF TREATMENT AND OFF STUDY CRITERIA', 'A genuine effort must be made to determine the reason(s) why a', 'participant fails to return for the necessary visits or is discontinued from', 'the trial. Information regarding the reason for not completing the trial', 'will be recorded on the appropriate case report forms.', 'It will be documented whether or not each patient completed the clinical', 'study. If for any patient study treatment or observations were', 'discontinued, the reason will be recorded on the appropriate case report', 'form. Reasons that a patient may discontinue participation in a clinical', 'study are listed below. All patients will be followed for survival until they', 'meet the criteria for off-study.', '10.1 Off Treatment Criteria', 'Clinical or radiographic evidence of progressive disease of', 'greater than 20% increase baseline target lesions selected', 'according to RECIST criteria', 'Adverse events/toxicity requiring removal from protocol therapy', 'Refusal of further protocol therapy by patient/parent/guardiar', 'Non-compliance that in the opinion of the investigator does not', 'allow for ongoing participation', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: RPPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 55 of 60', \"Physician determines it is not in the patient's best interest to\", 'continue on therapy', 'Repeated eligibility laboratory studies are outside the', 'parameters required for eligibility prior to the start of protocol', 'therapy', 'Study is terminated by the sponsor', 'Pregnancy', 'Development of a second malignancy', '10.2 Off Study Criteria', '.', 'Death', 'Lost to follow-up', 'Patient subsequent enrollment on another study with tumor', 'therapeutic intent (e.g. at recurrence) or additional non-protocol', 'anti-tumor therapy.', 'Withdrawal of consent for any further data submission', 'Patient did not receive protocol treatment after study enrollment', 'Withdrawal of consent', '11.0 SAFETY AND ADVERSE EVENT REPORTING REQUIREMENTS', '11.1 Reporting Adverse Experiences and Deaths to St. Jude IRB', 'Only \"unanticipated problems involving risks to participants or others\"', 'referred to hereafter as \"unanticipated problems\" are required to be', 'reported to the St. Jude IRB promptly, but in no event later than 10', 'working days after the investigator first learns of the unanticipated', 'problem. Regardless of whether the event is internal or external (for', 'example, an IND safety report by the sponsor pursuant to 21 CFR', '312.32), only adverse events that constitute unanticipated problems are', 'reportable to the St. Jude IRB. As further described in the definition of', \"unanticipated problem, this includes any event that in the PI's opinion\", 'was:', 'Unexpected (in terms of nature, severity, or frequency) given (1) the', 'research procedures that are described in the protocol-relate', 'documents, such as the IRB-approved research protocol and', 'informed consent document, as well as other relevant information', 'available about the research; (2) the observed rate of occurrence', '(compared to a credible baseline for comparison); and (3) the', 'characteristics of the subject population being studied; and', 'Related or possibly related to participation in the research; and', 'Serious; or if not serious suggests that the research places subjects', 'or others at a greater risk of harm (including physical,', 'psychological, economic, or social harm) than was previously', 'known or recognized.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}